Pacer Advisors Inc. Decreases Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Pacer Advisors Inc. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 17.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,142,491 shares of the specialty pharmaceutical company’s stock after selling 447,157 shares during the period. Pacer Advisors Inc. owned about 0.07% of Collegium Pharmaceutical worth $61,382,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COLL. JPMorgan Chase & Co. boosted its holdings in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after acquiring an additional 175,892 shares in the last quarter. Penserra Capital Management LLC acquired a new stake in Collegium Pharmaceutical in the 3rd quarter worth approximately $757,000. Barclays PLC grew its position in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after purchasing an additional 45,291 shares during the last quarter. Squarepoint Ops LLC increased its stake in Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after purchasing an additional 72,874 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Collegium Pharmaceutical in the second quarter worth $2,285,000.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 3.98% of the company’s stock.

Analyst Ratings Changes

COLL has been the topic of several research reports. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler restated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $43.80.

Collegium Pharmaceutical Trading Up 4.1 %

Collegium Pharmaceutical stock opened at $33.91 on Tuesday. The firm has a market cap of $1.09 billion, a PE ratio of 14.62 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 12 month low of $28.39 and a 12 month high of $42.29. The stock’s 50 day simple moving average is $30.74 and its two-hundred day simple moving average is $34.15. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.